Novavax Inc (NVAX) — Analysis Summary
Novavax Inc (NVAX) has a market cap of $1.38B with year-over-year revenue growth of +64.7%. Net margin stands at 39.2%. The stock trades at a P/E ratio of -15.8.
Key Takeaways
- Revenue changed +64.7% year-over-year
- Net margin of 39.2%
- P/E ratio of -15.8
Compared to other companies in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector, NVAX posted revenue growth of +64.7% and trades at a P/E of -15.8.
Novavax Inc (NVAX)
UPDATED — ET · SOURCE POLYGON
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Interest coverage at -3.6x — earnings do not cover interest payments
Revenue fell 46.9% vs the prior period.
Net income turned negative after a profitable prior period.
Shareholder equity is negative, which can signal balance-sheet stress.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees
749
Headquarters
GAITHERSBURG, MD
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Annual Dividend/Share
$1.27
Dividend Yield
15.14%
Dividend History
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.